Intellia Therapeutics, Inc.
0 products tracked · names used in filings: Intellia Therapeutics, Inc.
Upcoming milestones
lonvo-z: PDUFA target action date (hereditary angioedema (HAE))
Intellia Therapeutics, Inc. (NTLA); lonvoguran ziclumeran; BLA; status: set; "Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates - On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date - New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and mult"; filed 2026-11-05 · source
Recent milestones
No recent milestones.
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.